XPOVIO Online Discussion

Written by patrippon on February 3, 2021.

02/03/21

6:00 pm - 7:00 pm

Interactive clinical discussion:

XPOVIO® (selinexor), Now approved as early as 1st relapse in multiple myeloma.

By: Joseph Mikhael, MD – Translational Genomics Research Institute

RSVP:

866-914-9069

KAR0001187 – Please reference this number during registration